neutralizing

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

USP28-IN-3 is a highly selective USP28 inhibitor with an IC50 value of 0.1 μM against USP28.USP28-IN-3 exhibits anticancer activity and inhibits USP2, USP7, USP8, USP9x, UCHL3, and UCHL5.USP28-IN-3 is cytotoxic to human colorectal and lung squamous carcinoma cells, inhibiting c-cells and c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-cells through the ubiquitin-proteasome system. -proteasome system to dose-dependently downregulate cellular levels of c-Myc.

Succinic acid (1, 2-ethanedicarboxylic acid) is a product of anaerobic metabolism and an intermediate of the tricarboxylic acid cycle.

2-Amino-2-methyl-1-propanol (AMP) is an emulsifier, pH buffer, and surfactant used to prepare solutions with a pH of 8.7–10.4, exhibiting inhibitory effects against Plasmodium falciparum.

Mito-apocynin (C11) is a mitochondria-targeting antioxidant that works by targeting and neutralizing reactive oxygen species (ROS) produced during cellular respiration. Triphenylphosphonium bromide has been found to be effective in preventing mitochondrial dysfunction, which is a major cause of the aging process and various diseases. It has anti-inflammatory, anti-apoptotic and antioxidant activities.

JNJ4796 is an orally active fusion inhibitor of the influenza virus, inhibiting hemagglutinin (HA)-mediated fusion to neutralize the influenza A group 1 virus. JNJ4796 mimics the functionality of broadly neutralizing antibodies (bnAbs).

HIV-1inhibitor-77 (compound 13) is an HIV-1 inhibitor capable of neutralizing three different viruses: HIV-1CH58TF, HIV-1JRFL, and HIV-1AD8. The IC50 values for these viruses are 0.14 μM, 8.28 μM, and 2.92 μM, respectively.

(Rac)-BDA-366 (example 2) is the racemate of BDA-366, a potent Bcl-2 antagonist with a Ki of 3.3 nM. It shows high affinity and selectivity for the Bcl-2-BH4 domain. BDA-366 induces a conformational change in Bcl-2, neutralizing its anti-apoptotic function and converting Bcl-2 from a survival molecule into a cell death inducer. Additionally, BDA-366 can inhibit the growth of lung cancer cells.

TP-2 is a multi-cationic small molecule with a rhomboid shape, serving as an antidote capable of fully neutralizing unfractionated heparin (UFH) and low molecular weight heparin (LMWH). It surpasses protamine in neutralization efficacy and is also biocompatible.

Roxadimate (Ethyl dihydroxypropyl PABA) is used as a sunscreen agent, neutralizing free radicals and reducing oxidative stress. It protects cells from damage caused by radiation or neurotoxic injury and is applicable in the research of cancer and neurodegenerative diseases.

Riamilovir sodium (Triazavirin) is a novel guanine nucleoside analogue and broad-spectrum antiviral candidate. It completely blocks viral RNA synthesis and transcription by competitively inhibiting viral RNA-dependent RNA polymerase, demonstrating exceptionally potent in vitro neutralizing activity against various strains, including H5N1 avian influenza and multidrug-resistant variants.

Anti-MERS-2E6 mAb (MERS-2E6), a human IgG1 neutralizing antibody expressed in CHO cells, effectively competes with the virus Spike protein for binding to the CD26 receptor, thereby inhibiting viral invasion into host cells.

F8-S43-S3 is a highly effective entry inhibitor targeting enveloped viruses. It exhibits significant in vitro neutralizing activity against various influenza strains by binding to specific viral surface glycoproteins and interfering with the membrane fusion process.

Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.

STC314 is an anti-infective agent that reverses organ damage caused by excessive immune response by neutralizing extracellular histones and neutrophil trapping networks, and can be used in the study of sepsis and acute respiratory distress syndrome (ARDS).STC314 protects the stability of lipid bilayers, and inhibits platelet activation and erythrocyte damage.STC314 is also used in the study of prostate cancer.Nardeterol HCl is a selective kappa agonist with analgesic activity.

The COVID-19 Spike Protein mRNA, responsible for expressing the COVID-19 spike protein, is crucial for evaluating RNA delivery, translation efficiency, and cell viability. Positioned on the membrane surface, this spike protein facilitates virus entry into cells by binding to host cell membrane receptors and promoting membrane fusion. It serves as a significant action site for neutralizing antibodies and represents a primary focus in vaccine development [1].

COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) formulated with the novel coronavirus pneumonia spike protein, positioned on the membrane surface. It is designed for applications such as RNA delivery, translation efficiency, and cell viability assessment. This spike protein facilitates the COVID-19 virus's entry into host cells by binding to cell membrane receptors and enabling membrane fusion, making it a critical focal point for host neutralizing antibodies and vaccine development [1].

CKLF1-C27, a C-terminal peptide of CKLF1, effectively binds to and activates the CCR4 receptor, triggering the ERK1/2 pathway. Competing with CKLF1 for the CCR4 receptor, it neutralizes CKLF1's cellular effects. Additionally, CKLF1-C27 significantly promotes the proliferation of HUVECs and holds promise for psoriasis research [1].

[D-Pro4,D-Trp7,9,Nle11] Substance P (4-11) is a potent neurokinin NK1 antagonist that effectively inhibits the actions of gold-protein-substance P (GPSP) and substance P (SP), demonstrating its efficacy in neutralizing their effects [1].

The 2F5 epitope, a peptide gp41 (659-671), encompasses the complete sequential epitope recognized by one of the three broadly neutralizing antibodies against a wide range of primary HIV-1 isolates. This epitope is uniquely sequential and is identified by the 2F5 antibodies [1] [2].

Anti-MERS-D12 mAb is a fully human monoclonal neutralizing antibody isolated from a recovered patient. It binds specifically to the receptor-binding domain (RBD) of the MERS-CoV spike glycoprotein with extremely high affinity, effectively blocking the interaction between the virus and the host receptor dipeptidyl peptidase 4 (DPP4). This action exerts potent neutralizing activity by preventing viral attachment and entry into host cells.

Lenzilumab (KB 003) is a humanized granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody that directly binds to GM-CSF and prevents signaling through its receptor, and can be used to study COVID-19.

Motavizumab (MEDI-524) is a monoclonal antibody neutralizing respiratory syncytial virus (RSV), altering local and systemic cytokine responses in mouse models, used in the study of RSV infection.

Tabalumab (LY2127399) is a humanised monoclonal antibody targeting BAFF that neutralises both soluble and membrane-bound forms of BLyS and affects B-cell populations, and can be used for research into autoimmune diseases such as rheumatoid arthritis, kidney failure, and systemic lupus erythematosus.